Want to see HK:2135 full AI Analyst Report?
2135 Stock Chart & Stats
HK$0.11
>-HK$0.01(-1.01%)
At close: 4:00 PM EDT
HK$0.11
>-HK$0.01(-1.01%)
Day’s Range― - ―
52-Week RangeHK$0.09 - HK$0.20
Previous CloseN/A
Volume90.00K
Average Volume (3M)42.41K
Market Cap
HK$61.28M
Enterprise ValueHK$62.91
Total Cash (Recent Filing)HK$48.67M
Total Debt (Recent Filing)HK$49.84M
Price to Earnings (P/E)3.9
Beta0.69
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding557,077,330
10 Day Avg. Volume49,433
30 Day Avg. Volume42,411
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)0.70
Price to Sales (P/S)0.41
P/FCF Ratio2.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthReported revenue growth of 36.68% indicates meaningful expansion in the company’s operating base. If sustained, a larger revenue platform can improve fixed-cost absorption, support investment in aesthetic services, and provide a foundation for more durable profitability over the next several quarters.
Improved Cash GenerationStrong positive operating and free cash flow in 2025 marks a substantial improvement from the prior deficits. This strengthens internal funding capacity, reduces reliance on external financing, and gives management greater flexibility to maintain operations and invest in the business.
Manageable LeverageA debt-to-equity ratio near 0.55 suggests leverage is currently manageable and that the equity base remains substantial relative to borrowings. This provides some financial resilience and preserves capacity to navigate operating volatility without an excessive debt burden.
Bears Say
Thin Net ProfitabilityReturning to profit is encouraging, but a net margin of about 1% leaves limited protection against cost increases, weaker demand, or operating setbacks. Such a narrow margin means modest changes in revenue or expenses could materially reduce earnings and shareholder returns.
Multi-Year Earnings VolatilityLosses across several prior years indicate that profitability has not yet demonstrated consistency through the cycle. This history suggests earnings remain sensitive to demand and cost conditions, making the 2025 recovery less established as a durable operating trend.
Low Returns On EquityAn ROE of roughly 1.7% shows that the sizable equity base is generating only modest shareholder returns. The preceding negative ROE period further indicates weak capital efficiency, limiting the company’s ability to compound value without a sustained improvement in profitability.
Raily Aesthetic Medicine International Holdings Limited News
2135 FAQ
What was Raily Aesthetic Medicine International Holdings Limited’s price range in the past 12 months?
Raily Aesthetic Medicine International Holdings Limited lowest stock price was HK$0.09 and its highest was HK$0.20 in the past 12 months.
What is Raily Aesthetic Medicine International Holdings Limited’s market cap?
Raily Aesthetic Medicine International Holdings Limited’s market cap is HK$61.28M.
When is Raily Aesthetic Medicine International Holdings Limited’s upcoming earnings report date?
Raily Aesthetic Medicine International Holdings Limited’s upcoming earnings report date is Mar 26, 2027 which is in 186 days.
How were Raily Aesthetic Medicine International Holdings Limited’s earnings last quarter?
Raily Aesthetic Medicine International Holdings Limited released its earnings results on Aug 28, 2026. The company reported HK$0.008 earnings per share for the quarter.
Is Raily Aesthetic Medicine International Holdings Limited overvalued?
According to Wall Street analysts Raily Aesthetic Medicine International Holdings Limited’s price is currently Overvalued.
Does Raily Aesthetic Medicine International Holdings Limited pay dividends?
Raily Aesthetic Medicine International Holdings Limited does not currently pay dividends.
What is Raily Aesthetic Medicine International Holdings Limited’s EPS estimate?
Raily Aesthetic Medicine International Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Raily Aesthetic Medicine International Holdings Limited have?
Raily Aesthetic Medicine International Holdings Limited has 557,077,330 shares outstanding.
What happened to Raily Aesthetic Medicine International Holdings Limited’s price movement after its last earnings report?
Raily Aesthetic Medicine International Holdings Limited reported an EPS of HK$0.008 in its last earnings report. Following the earnings report the stock price went up 2.857%.
Which hedge fund is a major shareholder of Raily Aesthetic Medicine International Holdings Limited?
Currently, no hedge funds are holding shares in HK:2135
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Raily Aesthetic Medicine International Holdings Limited
Raily Aesthetic Medicine International Holdings Limited is an investment holding company primarily engaged in providing a comprehensive range of cosmetic medical services. Its operations are structured into three principal segments: Aesthetic Medical Services, Consulting Services, and the distribution of Aesthetic Medical Equipment Products. The company's service offerings include various aesthetic procedures such as: Surgical interventions: encompassing cosmetic surgeries performed on different areas of the face or body. Minimally invasive treatments: largely consisting of aesthetic injection procedures. Aesthetic dermatology: featuring diverse energy-based treatments. Aesthetic dental care: including orthodontic services, dental implants, and teeth whitening. Management consulting: providing specialized advisory services for aesthetic medical practices. Furthermore, Raily trades in medical equipment and sells surgical implants alongside aesthetic medical skincare products. The company manages and operates a network of four private, for-profit aesthetic medical clinics located in China's Zhejiang and Anhui Provinces. It serves a diverse clientele, including individual retail customers and other aesthetic medical institutions. Founded in 2008 and headquartered in Hangzhou, People's Republic of China, Raily Aesthetic Medicine International Holdings Limited operates as a subsidiary of Ruide Consultation Limited.
Raily Aesthetic Medicine International Holdings Limited (2135) Earnings & Revenues
Technical Analysis
Beauty Farm Medical & Health Industry, Inc.
―
Town Health International Medical Group Ltd.
―
Arrail Group Ltd.
―
Medicskin Holdings Ltd.
―
Saint Bella Inc.
―